Show simple item record

dc.contributor.authorChallis, Benjaminen
dc.contributor.authorCasey, Ruthen
dc.contributor.authorSimpson, HLen
dc.contributor.authorGurnell, Marken
dc.date.accessioned2016-12-08T15:31:53Z
dc.date.available2016-12-08T15:31:53Z
dc.date.issued2017-02en
dc.identifier.issn0300-0664
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/261496
dc.description.abstractPhaeochromocytomas and paragangliomas (PPGLs) are catecholamine secreting neuroendocrine tumours that predispose to haemodynamic instability. Currently, surgery is the only available curative treatment, but carries potential risks including hypertensive and hypotensive crises, cardiac arrhythmias, myocardial infarction and stroke, due to tumoral release of catecholamines during anaesthetic induction and tumour manipulation. The mortality associated with surgical resection of PPGL has significantly improved from 20-45% in the early 20th century (Apgar & Papper, AMA Archives of Surgery, 1951, 62, 634) to 0-2·9% in the early 21st century (Kinney et al. Journal of Cardiothoracic and Vascular Anesthesia, 2002, 16, 359), largely due to availability of effective pharmacological agents and advances in surgical and anaesthetic practice. However, surgical resection of PPGL still poses significant clinical management challenges. Preoperatively, alpha-adrenoceptor blockade is the mainstay of management, although various pharmacological strategies have been proposed, based largely on reports derived from retrospective data sets. To date, no consensus has been reached regarding the 'ideal' preoperative strategy due, in part, to a paucity of data from high-quality evidence-based studies comparing different treatment regimens. Here, based on the available literature, we address the $\textit{Clinical Question}$: Is there an optimal preoperative management strategy for PPGL?
dc.description.sponsorshipNational Institute for Health Research Cambridge Biomedical Research Centre
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.language.isoenen
dc.publisherWiley
dc.subjectHumansen
dc.subjectParagangliomaen
dc.subjectPheochromocytomaen
dc.subjectPostoperative Complicationsen
dc.subjectAdrenergic alpha-Antagonistsen
dc.subjectPreoperative Careen
dc.titleIs there an optimal preoperative management strategy for phaeochromocytoma/paraganglioma?en
dc.typeArticle
prism.endingPage167
prism.publicationDate2017en
prism.publicationNameClinical endocrinologyen
prism.startingPage163
prism.volume86en
dc.identifier.doi10.17863/CAM.6689
dcterms.dateAccepted2016-09-24en
rioxxterms.versionofrecord10.1111/cen.13252en
rioxxterms.versionAMen
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2017-02en
dc.contributor.orcidGurnell, Mark [0000-0001-5745-6832]
dc.identifier.eissn1365-2265
rioxxterms.typeJournal Article/Reviewen
rioxxterms.freetoread.startdate2017-10-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record